538 results on '"Mullins CD"'
Search Results
2. MSR72 Collaborative, Multisectoral, and Multidisciplinary Approach to Enhance FDA One Health Initiative Communication Strategies
3. PCR39 Patient and Caregiver Diversity in FDA Patient Engagement Activities and CBER-Regulated Therapeutics: A Review of the Literature
4. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations
5. What works when: mapping patient and stakeholder engagement methods along the ten-step continuum framework
6. A Dynamic Approach for Budget Impact Analysis (BIA) in Oncology: Nonmetastatic Castration-Resistant Prostate Cancer (NMCRPC) as an Illustrative Example
7. College Students' Preferences for Components of a Campus-Sponsored Program to Reduce Nonmedical Use of Prescription Stimulants
8. Cost-Effectiveness Of Grazoprevir / Elbasvir In Patients With Chronic Hepatitis C Virus
9. Costs Of End-Of-Life Treatments Among Elderly Metastatic Colon Cancer Patients
10. Early Assessment Of The 10-Step Patient Engagement Framework For Patient-Centered Outcomes Research Studies: The First 3 Steps
11. PRM61 - A Dynamic Approach for Budget Impact Analysis (BIA) in Oncology: Nonmetastatic Castration-Resistant Prostate Cancer (NMCRPC) as an Illustrative Example
12. PMH44 - College Students' Preferences for Components of a Campus-Sponsored Program to Reduce Nonmedical Use of Prescription Stimulants
13. PIN47 - Cost-Effectiveness Of Grazoprevir / Elbasvir In Patients With Chronic Hepatitis C Virus
14. PRM206 - Early Assessment Of The 10-Step Patient Engagement Framework For Patient-Centered Outcomes Research Studies: The First 3 Steps
15. PHS39 - Costs Of End-Of-Life Treatments Among Elderly Metastatic Colon Cancer Patients
16. Skeletal-Related Events And Mortality Among Seer-Medicare Patients With Metastatic Prostate Cancer: The Implications Of Measurement Approach
17. PMH1 METABOLIC SYNDROME AND SECOND GENERATION ANTIPSYCHOTICS UTILIZATION—IMPACT OF PSYCHIATRIC COMORBIDITY AND POLYPHARMACY
18. PMH13 ASSOCIATION OF MEDICATION PERSISTENCE AND HEALTH-CARE UTILIZATION IN HIGH-COST PATIENTS WITH MAJOR DEPRESSIVE DISORDER TREATED WITH DULOXETINE OR VENLAFAXINE XR
19. DB4 ECONOMIC EVALUATION OF THIAZOLIDINEDIONES AS ADD-ON THERAPY FOR TREATMENT OF TYPE 2 DIABETIC PATIENTS IN THE TAIWANESE NATIONAL HEALTH INSURANCE SYSTEM
20. PCV66 COSTS ASSOCIATED WITH DISCHARGES AGAINST MEDICAL ADVICE IN A CVD POPULATION
21. HT4 PRAGMATIC CLINICAL TRIALS FOR DRUG APPROVAL: IS IT REALISTIC?
22. PMH5 INFLUENCE OF PSYCHIATRIC COMORBIDITY AND POLYPHARMACY ON HOSPITALIZATION AND EXPENDITURES AMONG SECOND GENERATION ANTIPSYCHOTIC USERS WITH METABOLIC SYNDROME
23. PMH46 TREATMENT PERSISTENCE WITH DULOXETINE AND HEALTH CARE COSTS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER
24. PCN43 INITIAL COSTS OF TREATMENT AMONG STAGE IV PROSTATE CANCER (PCA) CHEMOTHERAPY PATIENTS IN SEER-MEDICARE
25. PCV133 THE COST-EFFECTIVENESS OF GENOTYPING CYP2C19 TO GUIDE ANTIPLATELET THERAPY SELECTION
26. PMS30 ADHERENCE TO DULOXETINE AND HOSPITAL UTILIZATION IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER AND CHRONIC PAIN
27. PCV134 READMISSIONS AFTER UNAUTHORIZED DISCHARGES IN THE CARDIOVASCULAR SETTING
28. PCN60 COST-EFFECTIVENESS OF OXALIPLATIN AND IRINOTECAN BASED COMBINATION THERAPY COMPARED WITH 5FU/LV FOR THE TREATMENT OF US ELDERLY ADVANCED COLON CANCER PATIENTS
29. PDB63 THE UTILIZATION OF ROSIGLITAZONE AND PIOGLITAZONE AFTER THE CARDIOVASCULAR RISK-WARNINGS: WAS THERE A DIFFERENTIAL EFFECT?
30. PHP36 HEALTH ECONOMICS DATA: USE AND PERCEIVED VALUE IN U.S. PAYERS' FORMULARY DECISIONS
31. PCN66 COST OF ANTHRACYCLINE-INDUCED CARDIOTOXICITY AMONG U.S. BREAST CANCER PATIENTS
32. PCN97 PHYSICIAN REFERRAL PATTERNS AMONG ELDERLY PATIENTS WITH STAGE IV PROSTATE CANCER (PCA): AN ANALYSIS USING SEERMEDICARE DATA
33. PCN62 FIRST YEAR COST EXPENDITURES ASSOCIATED WITH HEAD AND NECK CANCER DIAGNOSIS IN THE U.S. MANAGED CARE POPULATION
34. PMC36 THE POPULATION IMPACT OF CHEMOTHERAPY IN LATE-STAGE PROSTATE CANCER: A SIMULATION STUDY USING TAX327 AND SEER-MEDICARE DATA
35. PCN60 COSTS OF CARE FOR ELDERLY METASTATIC PROSTATE CANCER PATIENTS OVER TIME
36. PCN12 TIMING OF PHYSICIAN VISITS AND THE IMPACT ON SURVIVAL AMONG SEER-MEDICARE PATIENTS WITH STAGE IV PROSTATE CANCER
37. ND3 PRESCRIBING PATTERNS AMONG DEMENTIA PATIENTS AT THE VETERANS AFFAIRS MARYLAND HEALTH CARE SYSTEM (VAMHCS)
38. PCV81 ASSESSING THE IMPACT OF INCORPORATING PATIENT KNOWLEDGE AND BELIEFS INTO ANTICOAGULATION THERAPY MANAGEMENT SERVICES
39. PMH77 ANTIPSYCHOTIC METABOLIC PROPENSITY AND POLYTHERAPY: INFLUENCE ON HOSPITALIZATION
40. PRS10 TREATMENT COSTS ASSOCIATED WITH COMMUNITY ACQUIRED PNEUMONIA BY COMMUNITY LEVEL OF ANTIMICROBIAL RESISTANCE
41. WH1 BREAST CANCER PATIENTS' PREFERENCES FOR LOCAL AND SYSTEMIC THERAPY
42. PCV15 NEW DIAGNOSIS OF HYPERTENSION AMONG CELECOXIB AND NON-SELECTIVE NSAID USERS:A POPULATION-BASED COHORT STUDY
43. PCV21 ANTIHYPERTENSIVE DRUG BUDGET IMPACT OF THE ANGIOTENSIN II RECEPTOR BLOCKERS (ARB) IN THE UK
44. RS3 THE COST-EFFECTIVENESS OF TIOTROPIUM VERSUS IPRATROPIUM IN A US VETERANS POPULATION DIAGNOSED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
45. HP2 TRENDS IN ANGIOTENSIN II RECEPTOR BLOCKER (ARB) PRESCRIBING AMONG GENERAL PRACTITIONERS IN THE UK
46. PMH39 COMPARATIVE ANALYSIS OF DISCONTINUATION HAZARD FOR ATYPICAL ANTIPSYCHOTICS
47. PNL12 COST-EFFECTIVENESS OF ELETRIPTAN VERSUS SUMATRIPTAN: RESULTS FROM A RANDOMIZED, CONTROLLED TRIAL
48. HE3 DIFFERENTIAL RACIAL AND ETHNIC DISPARITIES IN HEALTH EXPENDITURE AND SELF-PERCEIVED HEALTH STATUS IN THE UNITED STATES
49. PHP23 EFFECT OF INSURANCE TYPE ON HEALTH PLANS' SPENDING ON SPECIALTY PHARMACEUTICALS: AN EMPIRICAL ANALYSIS
50. PG13 MAJOR GI EVENTS AMONG ELDERLY CHRONIC USERS OF COX-2SAND NON-SELECTIVE NSAIDS, WITH/WITHOUT ASPIRIN
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.